• Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM)

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming plenary oral presentation at the 29^th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), being hosted November 21 – 24, 2024 in Houston, TX. IN8bio will provide longer-term follow-up and additional data demonstrating the activity of its DRI gamma-delta T cell approach in solid tumors from the Phase 1 trial of INB-200. In June 2024, preliminary clinical data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating that 92% of evaluable patients treated in the investigator-initiated trial exceeded the median progression-free survival of 7 months typically observed using standard-of-care therapy with concomitant temozolomide (TMZ).

Details for the SNO oral presentation are as follows:

Title: INB-200: Fully Enrolled Phase 1 Study of Gene-Modified Autologous Gamma-Delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance Temozolomide (TMZ)

Presenter: Mina Lobbous, MD, MSPH, Assistant Professor, Cleveland Clinic Lerner College of Medicine
Abstract #: CTIM-09
Session Name: Abstract Session – Clinical Trials
Date and Time: Saturday, November 23, 2024, 11:25 AM - 11:35 AM CST

The abstract will be available online and can be accessed via the conference website at SNO 29^th Annual Meeting & Education Day.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on evaluating haplo-matched allogenic gamma-delta T cells given to patients with AML following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit www.IN8bio.com.

Investor & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
This email address is being protected from spambots. You need JavaScript enabled to view it. 
Patrick McCall
IN8bio, Inc.
646.933.5603
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
This email address is being protected from spambots. You need JavaScript enabled to view it.